Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026)

Caris Life Sciences' Share-based Compensation history runs 3 years deep, the most recent figure standing at $56000.0 for Q1 2026.

• In Q1 2026, Share-based Compensation fell 99.62% year-over-year to $56000.0; the TTM figure through Mar 2026 stood at -$10.8 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, up 431.17% from the prior year.
• Share-based Compensation for Q1 2026 stood at $56000.0, up from -$52.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $55.0 million in Q3 2025, with the low at -$52.8 million in Q4 2025.
• The 3-year median for Share-based Compensation is $56000.0 (2026), against an average of -$615857.1.
• Peak annual rise in Share-based Compensation reached 714.79% in 2025, while the deepest fall reached 7381.1% in 2025.
• Caris Life Sciences' Share-based Compensation stood at $725000.0 in 2024, then tumbled by 7381.1% to -$52.8 million in 2025, then soared by 100.11% to $56000.0 in 2026.
• Business Quant data shows CAI's Share-based Compensation at $56000.0 in Q1 2026, -$52.8 million in Q4 2025, and $55.0 million in Q3 2025.